Your Article Summary
See Latest ArticlesLocal treatment of prostate cancer using thermal-ablative energy
Der Urologe, 07/02/09
Muschter R - Thermal and thermal-ablative procedures for treating prostate cancer have been investigated systematically since approximately 1980 (apart from some historical predecessors), and numerous experimental and clinical reports have been published on this subject. The different options for thermal and thermal-ablative treatment of prostate cancer are very promising, but in light of the existing standard procedures, feasibility must not overrule reasonableness.
Related Articles
Computed radiography dual energy subtraction: Performance evaluation when detecting low-contrast lung nodules in an anthropomorphic phantom
Journal of Digital Imaging, 11/04/09
Relevance Score: 46%
Evidence that multiple genetic variants of MC4R play a functional role in the regulation of energy expenditure and appetite in Hispanic children
American Journal of Clinical Nutrition, 11/05/09
Relevance Score: 45%
Increased food energy supply is more than sufficient to explain the US epidemic of obesity
American Journal of Clinical Nutrition, 10/15/09
Relevance Score: 45%
The energy use associated with neural computation in the cerebellum
Journal of Cerebral Blood Flow & Metabolism, 11/12/09
Relevance Score: 44%
Effect of Femtosecond Laser Energy Level on Corneal Stromal Cell Death and Inflammation
Journal of Refractive Surgery, 10/19/09
Relevance Score: 43%
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature
European Urology, 12/04/09